A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Phase 1/2 Completed
281 enrolled 44 charts
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
Phase 1/2 Completed
28 enrolled
MIZAR-002
Phase 1/2 Completed
18 enrolled
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
Phase 1/2 Completed
26 enrolled 27 charts
KEYMAKER-U02
Phase 1/2 Completed
56 enrolled
ConsortiumIO
Phase 1/2 Completed
56 enrolled 11 charts
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Phase 1/2 Completed
89 enrolled 24 charts
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Phase 1/2 Completed
61 enrolled
CRIRIN
Phase 1/2 Completed
19 enrolled
KEYMAKER-U02
Phase 1/2 Completed
100 enrolled
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Phase 1/2 Completed
29 enrolled 15 charts
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
87 enrolled 22 charts
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Phase 1/2 Completed
307 enrolled 27 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
Phase 1/2 Completed
110 enrolled 27 charts
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
Phase 1/2 Completed
33 enrolled
RTA 408 Capsules in Patients With Melanoma - REVEAL
Phase 1/2 Completed
41 enrolled 15 charts
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Phase 1/2 Completed
30 enrolled
CONTRAC
Phase 1/2 Completed
12 enrolled 13 charts
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
Phase 1/2 Completed
191 enrolled 26 charts
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
Phase 1/2 Completed
395 enrolled 20 charts
DONIMI
Phase 1/2 Completed
44 enrolled
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
Phase 1/2 Completed
36 enrolled
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
Phase 1/2 Completed
320 enrolled 26 charts
Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
Phase 1/2 Completed
220 enrolled 19 charts
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Phase 1/2 Completed
224 enrolled 21 charts
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Phase 1/2 Completed
48 enrolled 13 charts
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
Phase 1/2 Completed
132 enrolled
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase 1/2 Completed
27 enrolled 16 charts
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Phase 1/2 Completed
74 enrolled
NMSC
Phase 1/2 Completed
26 enrolled
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Phase 1/2 Completed
79 enrolled
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Phase 1/2 Completed
12 enrolled
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
Phase 1/2 Completed
13 enrolled
Carac & PDT Combination in the Treatment Of Actinic Keratoses
Phase 1/2 Completed
60 enrolled
CombiRT
Phase 1/2 Completed
10 enrolled
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
Phase 1/2 Completed
10 enrolled 10 charts
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Phase 1/2 Completed
26 enrolled 13 charts
A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
Phase 1/2 Completed
24 enrolled 18 charts
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Phase 1/2 Completed
26 enrolled 47 charts
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Phase 1/2 Completed
5 enrolled 10 charts
Mel66
Phase 1/2 Completed
22 enrolled
DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients
Phase 1/2 Completed
8 enrolled
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
Phase 1/2 Completed
26 enrolled 8 charts
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
109 enrolled 25 charts
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
Phase 1/2 Completed
MEL60
Phase 1/2 Completed
50 enrolled 13 charts
Mel-65
Phase 1/2 Completed
33 enrolled